SCHEMBL25677271

SCHEMBL25677271

O=C(O)c1cc(Br)cc(C(=O)c2cc(Br)cc(C(F)(F)F)c2)c1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.57
SRD5A2 P31213 4/20 0.49
CES2 O00748 1/20 0.46
RXRA P19793 1/20 0.45
RXRB P28702 1/20 0.45
RXRG P48443 1/20 0.45
TAS2R14 Q9NYV8 1/20 0.43
P2RY14 Q15391 1/20 0.43
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
EPHX2 P34913 1/20 0.40
MRGPRX4 Q96LA9 2/20 0.39
ACP1 P24666 1/20 0.39
AKR1C3 P42330 1/20 0.39
AKR1C2 P52895 1/20 0.39
DHODH Q02127 1/20 0.38
DDR1 Q08345 2/20 0.38
POLB P06746 1/20 0.38
HCAR2 Q8TDS4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL494019 0.93 NOTUM (0.64) NOTUMSRD5A2CES2RXRARXRB
SCHEMBL22400366 0.86 NOTUM (0.57) NOTUMSRD5A2CES2RXRARXRB
SCHEMBL30688802 0.86 NOTUM (0.57) NOTUMSRD5A2CES2RXRARXRB
SCHEMBL545011 0.83 CES2 (0.62) NOTUMSRD5A2CES2RXRARXRB
SCHEMBL22400351 0.81 NOTUM (0.88) NOTUMCES2TAS2R14CNR1ACP1
SCHEMBL29528646 0.81 NOTUM (0.88) NOTUMCES2TAS2R14CNR1ACP1
SCHEMBL22400426 0.81 NOTUM (0.51) NOTUMSRD5A2CES2RXRARXRB
SCHEMBL30688823 0.81 NOTUM (0.51) NOTUMSRD5A2CES2RXRARXRB
SCHEMBL22400427 0.79 NOTUM (0.50) NOTUMACP1DDR1POLB
SCHEMBL503980 0.79 CES2 (0.70) SRD5A2CES2RXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230331745-A1 GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES NOVO NORDISK AS (DK) 2023-10-19 US disclosed
US-11767332-B2 Glucose-sensitive albumin-binding derivatives NOVO NORDISK A/S (DK) 2023-09-26 US disclosed
EP-4227313-A1 GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES Novo Nordisk A/S (DK) 2023-08-16 EP disclosed
EP-3707145-B1 GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES NOVO NORDISK AS (DK) 2023-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331745-A1 GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES ALB, DBI, FABP4 NOTUM 2218/4885SRD5A2 1626/4885CES2 991/4885
US-11767332-B2 Glucose-sensitive albumin-binding derivatives ALB, DBI, FABP4 NOTUM 2218/4885SRD5A2 1626/4885CES2 991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.